{"id":15678,"date":"2019-04-10T19:25:01","date_gmt":"2019-04-10T17:25:01","guid":{"rendered":"https:\/\/news.embl.de\/?p=15678"},"modified":"2024-03-22T10:56:28","modified_gmt":"2024-03-22T09:56:28","slug":"prioritising-cancer-drug-targets-using-crispr","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/","title":{"rendered":"Prioritising cancer drug targets using CRISPR"},"content":{"rendered":"\n<p>Researchers at the Wellcome Sanger Institute, Open Targets, EMBL\u2019s European Bioinformatics Institute (EMBL-EBI) and collaborators used CRISPR technology to disrupt every gene in over 300 cancer models. The results revealed thousands of genes that are essential for cancer survival, meaning they could be good candidates for cancer therapeutics.<\/p>\n\n\n\n<p>The researchers also developed a system to prioritise and rank the drug targets identified. The results, <a href=\"https:\/\/www.nature.com\/articles\/s41586-019-1103-9\">published in <em>Nature<\/em><\/a>, could accelerate the development of targeted cancer therapeutics.<\/p>\n\n\n\n<h2 class=\"my_style wp-block-heading\">Precision cancer treatments<\/h2>\n\n\n\n<p>The research is part of a wider project, called the Cancer Dependency Map, which aims to create a detailed rulebook for the precision treatment of cancer.<\/p>\n\n\n\n<p>For the current study, the researchers conducted one of the largest CRISPR screens of cancer genes to date, disrupting nearly 20,000 genes in over 300 cancer models from 30 cancer types to uncover which genes are critical for cancer survival. The team focused on common cancers, such as lung, colon and breast, and cancers of unmet clinical need, such as lung, ovarian and pancreatic, for which new treatments are urgently needed.<\/p>\n\n\n\n<h2 class=\"my_style wp-block-heading\">Guidance at a genome-scale<\/h2>\n\n\n\n<p>\u201cTo give a new drug the best chance of succeeding in the very final phases of clinical trials, it is crucial to select the best and most promising drug target at the beginning of the drug development process,\u201d said Francesco Iorio, Principal Staff Scientist at the Wellcome Sanger Institute and Open Targets. \u201cFor the first time, in a data-driven way, we provide guidance at a genome-scale on which new therapeutic targets should be put forward for the development of new anti-cancer drugs.\u201d<\/p>\n\n\n\n<p>It is expected that the collaborations between researchers, at Sanger and EMBL-EBI, and pharmaceutical companies within the Open Targets partnership, will bolster the translation of these research results into new treatments.<\/p>\n\n\n\n<p>&#8220;The research published in <em>Nature<\/em> today is the first fruition of a key strategy for Open Targets, using high throughput gene editing by the CRISPR-Cas9 system to identify new drug targets, not only in cancer but in future in our other key therapeutic areas of neurodegeneration and immunity,\u201d says Ian Dunham, Director of Open Targets. \u201cThis paper reveals a rich source of targets for potential intervention in cancer either directly or in combination therapies with existing drugs.&#8221;<\/p>\n\n\n\n<p>Read the full press release on the <a href=\"https:\/\/www.sanger.ac.uk\/news\/view\/new-cancer-drug-targets-accelerate-path-precision-medicine\">Wellcome Sanger website<\/a>.<\/p>\n\n\n\n<p>Visit the <a href=\"http:\/\/opentargets.org\/\" data-cke-saved-href=\"http:\/\/opentargets.org\/\">Open Targets<\/a> website.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment<\/p>\n","protected":false},"author":47,"featured_media":15680,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17591],"tags":[38,628,312,36,664,732],"embl_taxonomy":[],"class_list":["post-15678","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","category-science-technology","tag-cancer","tag-crispr","tag-drug-discovery","tag-embl-ebi","tag-genome","tag-sanger"],"acf":{"article_intro":"<p>CRISPR screen prioritises hundreds of genes for personalised cancer treatment<\/p>\n","related_links":[{"link_description":"Comprehensive protein data for drug development","link_url":"https:\/\/news.embl.de\/lab-matters\/pdbe-kb-launch\/"},{"link_description":"Transcription factors controlled by DNA sequence","link_url":"https:\/\/news.embl.de\/science\/transcription-factors-controlled-by-dna-sequence\/"}],"article_sources":[{"source_description":"<p>BEHAN, F.M., et al. (2019). Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening. <em>Nature<\/em>. Published online 10 05; DOI:\u00a010.1038\/s41586-019-1103-9<\/p>\n","source_link_url":"https:\/\/www.nature.com\/articles\/s41586-019-1103-9"}],"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Prioritising cancer drug targets using CRISPR | EMBL<\/title>\n<meta name=\"description\" content=\"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prioritising cancer drug targets using CRISPR | EMBL\" \/>\n<meta property=\"og:description\" content=\"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-10T17:25:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T09:56:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oana Stroe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Oana Stroe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\"},\"author\":{\"name\":\"Oana Stroe\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\"},\"headline\":\"Prioritising cancer drug targets using CRISPR\",\"datePublished\":\"2019-04-10T17:25:01+00:00\",\"dateModified\":\"2024-03-22T09:56:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg\",\"keywords\":[\"cancer\",\"crispr\",\"drug discovery\",\"embl-ebi\",\"genome\",\"sanger\"],\"articleSection\":[\"Science\",\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\",\"url\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\",\"name\":\"Prioritising cancer drug targets using CRISPR | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg\",\"datePublished\":\"2019-04-10T17:25:01+00:00\",\"dateModified\":\"2024-03-22T09:56:28+00:00\",\"description\":\"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg\",\"width\":620,\"height\":425,\"caption\":\"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment. IMAGE: Wellcome Sanger Institute\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\",\"name\":\"Oana Stroe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"caption\":\"Oana Stroe\"},\"description\":\"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.\",\"url\":\"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prioritising cancer drug targets using CRISPR | EMBL","description":"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/","og_locale":"en_US","og_type":"article","og_title":"Prioritising cancer drug targets using CRISPR | EMBL","og_description":"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment","og_url":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2019-04-10T17:25:01+00:00","article_modified_time":"2024-03-22T09:56:28+00:00","og_image":[{"width":620,"height":425,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","type":"image\/jpeg"}],"author":"Oana Stroe","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Oana Stroe","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/"},"author":{"name":"Oana Stroe","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414"},"headline":"Prioritising cancer drug targets using CRISPR","datePublished":"2019-04-10T17:25:01+00:00","dateModified":"2024-03-22T09:56:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/"},"wordCount":387,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","keywords":["cancer","crispr","drug discovery","embl-ebi","genome","sanger"],"articleSection":["Science","Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/","url":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/","name":"Prioritising cancer drug targets using CRISPR | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","datePublished":"2019-04-10T17:25:01+00:00","dateModified":"2024-03-22T09:56:28+00:00","description":"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science\/prioritising-cancer-drug-targets-using-crispr\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","width":620,"height":425,"caption":"Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment. IMAGE: Wellcome Sanger Institute"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414","name":"Oana Stroe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","caption":"Oana Stroe"},"description":"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.","url":"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/04\/SAEZ-RODRIGUEZ_Nature_CRISRP_620x425-e1554903153683.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=15678"}],"version-history":[{"count":9,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15678\/revisions"}],"predecessor-version":[{"id":19427,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15678\/revisions\/19427"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/15680"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=15678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=15678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=15678"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=15678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}